A B S T R A C T

Background
Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and is widely available in other countries worldwide. This review sought to evaluate the efficacy and safety of oral tenoxicam in acute postoperative pain, using clinical studies of patients with established pain, and with outcomes measured primarily over 6 hours using standard methods. This type of study has been used for many decades to establish that drugs have analgesic properties.
Objectives
To assess the efficacy of single dose oral tenoxicam in acute postoperative pain, and any associated adverse events. 
Search methods
We searched
Selection criteria
Randomised, double-blind, placebo-controlled clinical trials of oral tenoxicam for relief of acute postoperative pain in adults.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. The area under the "pain relief versus time" curve was used to derive the proportion of participants with tenoxicam experiencing least 50% pain relief over 4 to 6 hours, using validated equations. The number needed to treat to benefit (NNT) was calculated using 95% confidence intervals (CI). The proportion of participants using rescue analgesia over a specified time period, and time to use of rescue analgesia, were sought as additional measures of efficacy. Information on adverse events and withdrawals was also collected.
Main results
Not one of sixteen studies identified by the searches and examined in detail studied oral tenoxicam in patients with established postoperative pain and therefore no results are available.
In the absence of evidence of efficacy for oral tenoxicam in acute postoperative pain, its use in this indication is not justified at present. Because trials clearly demonstrating analgesic efficacy in the most basic of acute pain studies is lacking, use in other indications should be evaluated carefully. Given the large number of available drugs of this and similar classes which are effective, there is no urgent research agenda for this particular drug.
P L A I N L A N G U A G E S U M M A R Y
Single dose oral tenoxicam for acute postoperative pain in adults
Pain is commonly experienced after surgical procedures. Acute postoperative pain of moderate or severe intensity is often used (as a model) to test whether or not drugs are effective painkillers. In this case we could find no studies that tested oral tenoxicam against placebo. It is possible that the studies were done, but not reported, because they were used only to register tenoxicam with licensing authorities throughout the world. However, this leaves an important gap in our knowledge, and it means that we cannot be confident about using oral tenoxicam for acute painful conditions.
B A C K G R O U N D
Acute pain occurs as a result of tissue damage either accidentally due to an injury or as a result of surgery. Acute postoperative pain is a manifestation of inflammation due to tissue injury. The management of postoperative pain and inflammation is a critical component of patient care. This is one of a series of reviews whose aim is to present evidence for relative analgesic efficacy through indirect comparisons with placebo, in very similar trials performed in a standard manner, with very similar outcomes, and over the same duration. Such relative analgesic efficacy does not in itself determine choice of drug for any situation or patient, but guides policy-making at the local level. Recently published reviews include paracetamol 
Acute pain trials
Single dose trials in acute pain are commonly short in duration, rarely lasting longer than 12 hours. The numbers of participants is small, allowing no reliable conclusions to be drawn about safety. To show that the analgesic is working it is necessary to use placebo (McQuay 2005) . There are clear ethical considerations in doing this. These ethical considerations are answered by using acute pain situations where the pain is expected to go away, and by providing additional analgesia, commonly called rescue analgesia, if the pain has not diminished after about an hour. This is reasonable, because not all participants given an analgesic will have significant pain relief. Approximately 18% of participants given placebo will have significant pain relief (Moore 2006), and up to 50% may have inadequate analgesia with active medicines. The use of additional or rescue analgesia is hence important for all participants in the trials. Clinical trials measuring the efficacy of analgesics in acute pain have been standardised over many years. Trials have to be randomised and double blind. Typically, in the first few hours or days after an operation, patients develop pain that is moderate to severe in intensity, and will then be given the test analgesic or placebo. Pain is measured using standard pain intensity scales immediately before the intervention, and then using pain intensity and pain relief scales over the following 4 to 6 hours for shorter acting drugs, and up to 12 or 24 hours for longer acting drugs. Pain relief of half the maximum possible pain relief or better (at least 50% pain relief ) is typically regarded as a clinically useful outcome. For patients given rescue medication it is usual for no additional pain measurements to be made, and for all subsequent measures to be recorded as initial pain intensity or baseline (zero) pain relief (baseline observation carried forward). This process ensures that analgesia from the rescue medication is not wrongly ascribed to the test intervention. In some trials the last observation is carried forward, which gives an inflated response for the test intervention compared to placebo, but the effect has been shown to be negligible over 4 to 6 hours (Moore 2005). Patients usually remain in the hospital or clinic for at least the first 6 hours following the intervention, with measurements supervised, although they may then be allowed home to make their own measurements in trials of longer duration. 
O B J E C T I V E S
To assess the efficacy and adverse effects of single dose oral tenoxicam for acute postoperative pain using methods that permit comparison with other analgesics evaluated in standardised trials using almost identical methods and outcomes.
M E T H O D S Criteria for considering studies for this review
Types of studies
Studies would be included if they were double blind trials of single dose oral tenoxicam compared with placebo for the treatment of moderate to severe postoperative pain in adults with at least 10 participants randomly allocated to each treatment group. Multiple dose studies will be included if appropriate data from the first dose were available. Cross-over studies were included provided that data from the first arm were presented separately. The following were excluded:
• review articles, case reports, and clinical observations; • studies of experimental pain;
• studies where pain relief is assessed only by clinicians, nurses or carers (i.e., not patient-reported);
• studies of less than four hours duration or studies that fail to present data over four to six hours post-dose.
For postpartum pain, studies were included if the pain investigated was due to episiotomy or Caesarean section irrespective of the presence of uterine cramps; studies investigating pain due to uterine cramps alone were excluded.
Types of participants
Studies of adult participants (> 15 yrs) with established postoperative pain of moderate to severe intensity following day surgery or in-patient surgery were included. For studies using a visual analogue scale (VAS), pain of at least moderate intensity were equated to greater than 30 mm (Collins 1997).
Types of interventions
Tenoxicam or matched placebo administered as a single oral dose for postoperative pain.
Types of outcome measures
Data was collected on the following outcomes:
• participant characteristics;
• patient reported pain at baseline (physician, nurse or carer reported pain will not be included in the analysis);
• patient reported pain relief expressed at least hourly over four to six hours using validated pain scales (pain intensity and pain relief in the form of VAS or categorical scales, or both);
• patient global assessment of efficacy (PGE), using a standard categorical scale;
• time to use of rescue medication;
• number of participants using rescue medication;
• number of participants with one or more adverse events;
• number of participants with serious adverse events;
• number of withdrawals (all cause, adverse event).
Search methods for identification of studies
To identify studies for inclusion in this review, the following electronic databases were searched: Please see Appendix 1 for the MEDLINE search strategy, Appendix 2 for the EMBASE search strategy and Appendix 3 for the Cochrane CENTRAL search strategy. Additional studies were sought from the reference lists of retrieved articles and reviews.
Language
No language restriction was applied.
Unpublished studies
No manufacturing or distributing pharmaceutical company was contacted for unpublished trial data.
Data collection and analysis
Selection of studies
Two review authors independently assessed and agreed the search results for studies that might be included in the review.
Quality assessment
Two review authors independently assessed the included studies for quality using a five-point scale (Jadad 1996b) that considers randomisation, blinding, and study withdrawals and dropouts.
Data management
Data were extracted by two review authors and recorded on a standard data extraction form. Data suitable for pooling were entered into RevMan 5.0.17.
Data analysis
For each study, the mean TOTPAR, SPID, VAS TOTPAR or VAS SPID (Appendix 4) values for active and placebo were converted to %maxTOTPAR or %maxSPID by division into the calculated maximum value (Cooper 1991). The proportion of participants in each treatment group who achieved at least 50%maxTOTPAR was calculated using verified equations (Moore 1996; Moore 1997a; Moore 1997b). These proportions were converted into the number of participants achieving at least 50%maxTOTPAR by multiplying by the total number of participants in the treatment group. Information on the number of participants with at least 50%max-TOTPAR for active and placebo was used to calculate relative benefit/relative risk (RR), and number-needed-to-treat-to-benefit (NNT). Pain measures accepted for the calculation of TOTPAR or SPID were:
• five-point categorical pain relief (PR) scales with comparable wording to "none, slight, moderate, good or complete";
• four-point categorical pain intensity (PI) scales with comparable wording to "none, mild, moderate, severe";
• VAS for pain relief;
• VAS for pain intensity.
If none of these measures was available, the number of participants reporting "very good or excellent" on a five-point categorical global scale with the wording "poor, fair, good, very good, excellent" were used for the number of participants achieving at least 50% pain relief (Collins 2001). The number of participants reporting treatment-emergent adverse effects was extracted for each treatment group. RR estimates were calculated with 95% confidence intervals (CI) using a fixedeffect model (Morris 1995). NNT/Number-needed-to-treat-toharm (NNH) and 95% CIs were calculated using the pooled number of events using the method devised by Cook and Sackett (Cook 1995). A statistically significant difference from control was assumed when the 95% CI of the RR did not include the number one. Homogeneity was examined visually using L'Abbé plots (L'Abbé 1987). Sub-group analyses were planned to determine the effect of dose, presenting condition (pain model), and high versus low (two or fewer versus three or more) quality trials. A minimum of two studies and 200 participants must be available in any sensitivity analysis (Moore 1998).
R E S U L T S Description of studies
Results of the search
Sixteen studies were examined in detail by reading abstracts and the full paper obtained in electronic or paper format.
Included studies
No studies were found matching the inclusion criteria.
Excluded studies
All the sixteen studies examined were excluded. Four studies were excluded because they were studies of preemptive analgesia in which tenoxicam was administered before participants had established pain (Blake 1997; Colbert 1998; Moiniche 1995; Roelofse 1996a). Two studies had no extractable data for the first 6 hours that could be used (Callesen 1999; Eggers 1999). Three studies had no placebo arm (Cassaro 1990 
Risk of bias in included studies
There were no included studies, so bias could not be evaluated.
Effects of interventions
There were no included studies, so effects could not be evaluated.
D I S C U S S I O N
Tenoxicam is a widely available NSAID, in many parts of the world, and is available by oral, rectal, and intravenous or intramuscular injection. It is disappointing that no classical analgesic studies of efficacy of oral tenoxicam compared with placebo in patients with established pain have been published.
It is almost certain that such studies have been performed, as they would have been required for registration purposes. Previously, large numbers of unpublished trials of this design have been included in systematic reviews of tramadol (Moore 1997c), and large numbers of analgesic trials of many designs with dexketoprofen (Moore 2008). Obtaining unpublished clinical trial data is, however, a long and complicated process, made more difficult by drugs being older, and with original trial data hard to find.
There is a literature showing that tenoxicam has analgesic properties in acute pain, but most of those were studies of intravenous use perioperatively in patients without established pain. While in general these studies showed some efficacy of tenoxicam, the disparate nature of designs, doses, and conditions, predominantly without any placebo comparator, means that there is little in the way of conventional evidence of efficacy for oral tenoxicam in postoperative pain.
Some studies were large, and may have utility in assessing adverse events. For instance, one study examined perioperative intravenous plus postoperative oral tenoxicam (80 mg perioperatively and 40 mg orally for each over four days) (Merry 1998). Surgical site bleeding was somewhat higher with tenoxicam, and in up to 10% of participants in otorhinolaryngology surgery.
A U T H O R S ' C O N C L U S I O N S Implications for practice
In the absence of evidence of efficacy for oral tenoxicam in acute postoperative pain, its use in this indication is not justified. Because trials clearly demonstrating analgesic efficacy in the most basic of acute pain studies is lacking, use in other indications should be evaluated carefully.
Implications for research
Given the large number of available drugs of this and similar classes to treat postoperative pain, there is no urgent research agenda.
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TOTPAR:
Total pain relief (TOTPAR) is calculated as the sum of pain relief scores over a period of time. If a patient had complete pain relief immediately after taking an analgesic, and maintained that level of pain relief for six hours, they would have a six-hour TOTPAR of the maximum of 24. Differences between pain relief values at the start and end of a measurement period are dealt with by the trapezoidal rule. This is a simple method that approximately calculates the definite integral of the area under the pain relief curve by calculating the sum of the areas of several trapezoids that together closely approximate to the area under the curve.
SPID:
Summed pain intensity difference (SPID) is calculated as the sum of the differences between the pain scores over a period of time. Differences between pain intensity values at the start and end of a measurement period are dealt with by the trapezoidal rule. 
VAS TOTPAR and VAS SPID
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